SYLVANT Receives FDA Approval to Treat Multicentric Castleman's Disease

SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced interleukin-6 in a nonclinical study.

http://ift.tt/1mQwHuz